Moomoo AI 已提取核心信息
On February 21, 2024, Novo Integrated Sciences, Inc. (Novo), along with its wholly-owned subsidiary Clinical Consultants International, LLC (CCI), announced a new Consulting Services Agreement with Futura Surgicare Pvt Ltd, a leading manufacturer of wound closure and surgical products known as Dolphin Sutures. The agreement aims to assist Futura in obtaining U.S. FDA 510K approvals for its advanced surgical products and to establish a strategic partnership for introducing Dolphin Sutures and mesh products to the North American healthcare market. This partnership is expected to bring cost savings and improved care to American patients and healthcare providers. Novo Integrated Sciences, headquartered in Bellevue, Washington, is focused on a multidisciplinary approach to patient-first health and wellness, integrating medical technology, advanced therapeutics, and rehabilitative science. The company operates on a decentralized healthcare model, emphasizing service networks, technology, and product development to enhance non-catastrophic healthcare delivery.
On February 21, 2024, Novo Integrated Sciences, Inc. (Novo), along with its wholly-owned subsidiary Clinical Consultants International, LLC (CCI), announced a new Consulting Services Agreement with Futura Surgicare Pvt Ltd, a leading manufacturer of wound closure and surgical products known as Dolphin Sutures. The agreement aims to assist Futura in obtaining U.S. FDA 510K approvals for its advanced surgical products and to establish a strategic partnership for introducing Dolphin Sutures and mesh products to the North American healthcare market. This partnership is expected to bring cost savings and improved care to American patients and healthcare providers. Novo Integrated Sciences, headquartered in Bellevue, Washington, is focused on a multidisciplinary approach to patient-first health and wellness, integrating medical technology, advanced therapeutics, and rehabilitative science. The company operates on a decentralized healthcare model, emphasizing service networks, technology, and product development to enhance non-catastrophic healthcare delivery.
2024年2月21日，Novo Integrated Sciences, Inc.（Novo）及其全资子公司临床顾问国际有限责任公司（CCI）宣布与Futura Surgicare Pvt Ltd签订新的咨询服务协议，该公司是伤口闭合和手术产品的领先制造商，名为Dolphin Sutures。该协议旨在协助Futura的先进外科产品获得美国食品药品管理局510K的批准，并建立战略合作伙伴关系，将Dolphin Sutures和网状产品引入北美医疗市场。预计这种伙伴关系将为美国患者和医疗保健提供者节省成本并改善医疗服务。总部位于华盛顿州贝尔维尤的Novo Integrated Sciences专注于以多学科方法实现患者至上的健康和保健，整合了医疗技术、先进疗法和康复科学。该公司以分散的医疗模式运营，强调服务网络、技术和产品开发，以增强非灾难性医疗保健的提供。
2024年2月21日，Novo Integrated Sciences, Inc.（Novo）及其全资子公司临床顾问国际有限责任公司（CCI）宣布与Futura Surgicare Pvt Ltd签订新的咨询服务协议，该公司是伤口闭合和手术产品的领先制造商，名为Dolphin Sutures。该协议旨在协助Futura的先进外科产品获得美国食品药品管理局510K的批准，并建立战略合作伙伴关系，将Dolphin Sutures和网状产品引入北美医疗市场。预计这种伙伴关系将为美国患者和医疗保健提供者节省成本并改善医疗服务。总部位于华盛顿州贝尔维尤的Novo Integrated Sciences专注于以多学科方法实现患者至上的健康和保健，整合了医疗技术、先进疗法和康复科学。该公司以分散的医疗模式运营，强调服务网络、技术和产品开发，以增强非灾难性医疗保健的提供。
有用
没用